![]() |
Name |
Terpestacin B
|
Molecular Formula | C25H38O5 | |
IUPAC Name* |
(1S,2E,5R,9S,11E,15S,16R)-7,15-dihydroxy-6-[(2S)-1-hydroxypropan-2-yl]-2,9,12,16-tetramethyl-19-oxatricyclo[14.2.1.05,9]nonadeca-2,6,11-trien-8-one
|
|
SMILES |
C/C/1=C\C[C@]2([C@H](C/C=C(/[C@@H]3CC[C@@](O3)([C@H](CC1)O)C)\C)C(=C(C2=O)O)[C@H](C)CO)C
|
|
InChI |
InChI=1S/C25H38O5/c1-15-6-9-20(27)25(5)13-11-19(30-25)16(2)7-8-18-21(17(3)14-26)22(28)23(29)24(18,4)12-10-15/h7,10,17-20,26-28H,6,8-9,11-14H2,1-5H3/b15-10+,16-7+/t17-,18-,19+,20+,24+,25-/m1/s1
|
|
InChIKey |
LAJNGEKHZMZDRF-ZPIROSACSA-N
|
|
Synonyms |
Terpestacin B
|
|
CAS | NA | |
PubChem CID | 146683287 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 418.6 | ALogp: | 2.3 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 30 | QED Weighted: | 0.554 |
Caco-2 Permeability: | -4.715 | MDCK Permeability: | 0.00002130 |
Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.137 | 20% Bioavailability (F20%): | 0.763 |
30% Bioavailability (F30%): | 0.969 |
Blood-Brain-Barrier Penetration (BBB): | 0.973 | Plasma Protein Binding (PPB): | 77.16% |
Volume Distribution (VD): | 0.74 | Fu: | 12.01% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.261 |
CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.781 |
CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.042 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.129 |
CYP3A4-inhibitor: | 0.661 | CYP3A4-substrate: | 0.598 |
Clearance (CL): | 10.492 | Half-life (T1/2): | 0.125 |
hERG Blockers: | 0.034 | Human Hepatotoxicity (H-HT): | 0.194 |
Drug-inuced Liver Injury (DILI): | 0.188 | AMES Toxicity: | 0.136 |
Rat Oral Acute Toxicity: | 0.223 | Maximum Recommended Daily Dose: | 0.939 |
Skin Sensitization: | 0.957 | Carcinogencity: | 0.487 |
Eye Corrosion: | 0.034 | Eye Irritation: | 0.055 |
Respiratory Toxicity: | 0.934 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005685 | ![]() |
1.000 | D04GJN | ![]() |
0.263 | ||
ENC001882 | ![]() |
0.656 | D04VIS | ![]() |
0.263 | ||
ENC003560 | ![]() |
0.656 | D0K0EK | ![]() |
0.261 | ||
ENC002974 | ![]() |
0.656 | D0KR5B | ![]() |
0.256 | ||
ENC005684 | ![]() |
0.626 | D0C7JF | ![]() |
0.254 | ||
ENC003210 | ![]() |
0.532 | D0R7JT | ![]() |
0.252 | ||
ENC005683 | ![]() |
0.532 | D06XMU | ![]() |
0.250 | ||
ENC006130 | ![]() |
0.488 | D0L2LS | ![]() |
0.248 | ||
ENC003502 | ![]() |
0.396 | D0IX6I | ![]() |
0.246 | ||
ENC004376 | ![]() |
0.383 | D0D1SG | ![]() |
0.246 |